UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as |
|
| Industry | Medical |
| Founded | 1989 |
| Founder | Peter C. Farrell (Founder and Chairman) |
| Headquarters | San Diego, California |
|
Key people
|
Michael "Mick" Farrell (CEO) Robert Douglas (President and COO) |
| Products | Medical equipment for sleep-disordered breathing and other respiratory disorders |
| Website | resmed |
ResMed is a global manufacturer of CPAP masks, machines and other products that diagnose, treat or help manage sleep-disordered breathing (particularly sleep apnea), chronic obstructive pulmonary disease (COPD), or other respiratory conditions. For the general public, the company offers a non-contact sleep monitor, the S+ by ResMed, currently available in the US.
ResMed employs about 5,000 employees worldwide, operates in 100 countries and has manufacturing facilities in Australia, France, Singapore and the US. It achieved revenues of $1.7 billion USD in fiscal year 2014–15.
As part of its mission, ResMed seeks to spread awareness of the prevalence of sleep-disordered breathing (SDB) and its major manifestation, obstructive sleep apnea (OSA), since more than 80% of cases are believed to be undiagnosed. More than 70% of people with obesity, heart failure, type 2 diabetes, and drug-resistant hypertension have some form of sleep-disordered breathing.
In 1980, Professor Colin Sullivan invented the first continuous positive airway pressure (CPAP) machine, regarded today as the “gold standard” in sleep apnea treatment. ResMed launched in 1989 when founder Peter Farrell sought to expand the general public’s access to CPAP treatment. The company was founded in Australia in 1989, but relocated to San Diego in 1990. In addition to CPAP machines and masks, the company has since grown to produce CPAP humidifiers, heated tubes and other accessories, as well as diagnostic tools, hospital CPAP machines and life support ventilators. It has also expanded into healthcare informatics, with software solutions that enable patients and medical professionals to wirelessly monitor sleep data.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2023 | 2022-10-26 | Future report Set alerts | |
| Q4 2022 | 2022-08-11 | 1.49 | 1.49 |
| Q3 2022 | 2022-04-28 | 1.32 | 1.32 |
| Q2 2022 | 2022-01-27 | 1.47 | 1.47 |
| Q1 2022 | 2021-10-28 | 1.51 | 1.51 |
| Q4 2021 | 2021-08-05 | 1.35 | 1.35 |
| Q3 2021 | 2021-04-29 | 1.30 | 1.30 |
| Q2 2021 | 2021-01-28 | 1.41 | 1.41 |
| Q1 2021 | 2020-10-29 | 1.27 | 1.27 |
| Q4 2020 | 2020-08-05 | 1.33 | 1.33 |
| 2016-07-10 | Reiterated Rating | Bank of America Corp. | Hold | $65.00 |
| 2016-06-27 | Downgrade | Needham & Company LLC | Hold to Underperform | |
| 2016-04-27 | Reiterated Rating | BMO Capital Markets | Hold | |
| 2016-04-27 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-04-27 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2016-04-27 | Upgrade | Macquarie | Underperform to Neutral | |
| 2016-04-27 | Upgrade | Citigroup Inc. | Neutral to Buy | |
| 2016-04-27 | Downgrade | Piper Jaffray | Overweight to Neutral | $65.00 to $57.00 |
| 2016-04-27 | Downgrade | Piper Jaffray Cos. | Overweight to Neutral | $65.00 to $57.00 |
| 2016-04-07 | Initiated Coverage | Barclays | Underweight | $55.00 |
| 2016-04-07 | Initiated Coverage | Barclays PLC | Underweight | $55.00 |
| 2016-02-29 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2016-02-23 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2016-02-23 | Reiterated Rating | Canaccord Genuity | Hold | $54.00 to $56.50 |
| 2016-02-23 | Reiterated Rating | Barclays | Underweight | |
| 2016-01-22 | Upgrade | Credit Suisse | Neutral to Outperform | |
| 2016-01-22 | Upgrade | Credit Suisse Group AG | Neutral to Outperform | |
| 2016-01-19 | Downgrade | Barclays | Equal Weight to Underweight | $61.00 to $52.00 |
| 2015-12-17 | Downgrade | Needham & Company LLC | Buy to Hold | |
| 2015-10-23 | Reiterated Rating | Canaccord Genuity | Hold | $54.00 |
| 2015-10-23 | Reiterated Rating | Needham & Company LLC | Buy | $66.00 |
| 2015-10-09 | Lower Price Target | BMO Capital Markets | $60.00 to $57.00 | |
| 2015-10-06 | Upgrade | Deutsche Bank | Sell to Hold | $53.00 to $56.00 |
| 2015-10-06 | Upgrade | Deutsche Bank AG | Sell to Hold | $53.00 to $56.00 |
| 2015-09-24 | Upgrade | Goldman Sachs | Neutral to Conviction-Buy | |
| 2015-09-24 | Upgrade | Goldman Sachs Group Inc. | Neutral to Conviction-Buy | |
| 2015-08-26 | Reiterated Rating | Needham & Company LLC | Buy | $83.00 |
| 2015-08-16 | Reiterated Rating | Needham & Company LLC | Buy | $66.00 |
| 2015-08-02 | Reiterated Rating | Needham & Company LLC | Buy | $65.00 to $66.00 |
| 2015-07-31 | Reiterated Rating | Canaccord Genuity | Hold | $54.00 |
| 2015-07-31 | Upgrade | Morgan Stanley | Equal Weight to Overweight | |
| 2015-07-31 | Downgrade | Deutsche Bank | Hold to Sell | $61.00 to $53.00 |
| 2015-07-13 | Downgrade | Macquarie | Neutral to Underperform | |
| 2015-06-25 | Initiated Coverage | Barclays | Equal Weight | $61.00 |
| 2015-06-08 | Reiterated Rating | Piper Jaffray | Overweight | $80.00 |
| 2015-06-08 | Reiterated Rating | Needham & Company LLC | Buy | $65.00 |
| 2015-05-14 | Set Price Target | Jefferies Group | Hold | $65.00 to $52.00 |
| 2015-05-14 | Lower Price Target | Needham & Company LLC | Buy | $77.00 to $65.00 |
| 2015-05-14 | Reiterated Rating | Canaccord Genuity | Hold | $54.00 |
| 2015-05-13 | Downgrade | Bank of America | Buy to Neutral | |
| 2015-05-13 | Downgrade | Bank of America Corp. | Buy to Neutral | |
| 2015-04-27 | Downgrade | Goldman Sachs | Buy to Neutral | |
| 2015-04-26 | Reiterated Rating | Canaccord Genuity | Hold | $54.00 |
| 2015-04-24 | Boost Price Target | BMO Capital Markets | Market Perform | $60.00 to $66.00 |
| 2015-04-24 | Downgrade | Macquarie | Outperform to Neutral | |
| 2015-04-07 | Upgrade | Credit Suisse | Neutral to Outperform | |
| 2015-03-25 | Boost Price Target | Jefferies Group | Hold | $52.00 to $65.00 |
| 2015-01-27 | Boost Price Target | Northland Securities | Hold to Under Perform | $40.00 to $44.00 |
| 2015-01-23 | Boost Price Target | Canaccord Genuity | Hold | $42.00 to $50.00 |
| 2015-01-23 | Upgrade | Needham & Company LLC | Hold to Buy | $77.00 |
| 2014-11-18 | Boost Price Target | Morgan Stanley | Equal Weight | $49.57 to $52.39 |
| 2014-10-24 | Reiterated Rating | Morgan Stanley | Equal Weight | $46.19 to $49.57 |
| 2014-10-24 | Upgrade | William Blair | Market Perform to Outperform | |
| 2014-08-01 | Lower Price Target | Piper Jaffray | $55.00 to $53.00 | |
| 2014-08-01 | Lower Price Target | Canaccord Genuity | $43.00 to $39.00 | |
| 2014-08-01 | Reiterated Rating | Jefferies Group | Hold | $40.00 to $42.00 |
| 2014-07-03 | Downgrade | Deutsche Bank | Buy to Hold | $52.00 |
| 2014-06-10 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | |
| 2014-05-27 | Downgrade | Northland Securities | Market Perform to Underperform | $40.00 |
| 2014-04-24 | Upgrade | Deutsche Bank | Hold to Buy | $52.00 |
| 2014-04-24 | Reiterated Rating | Morgan Stanley | Equal Weight | $46.08 |
| 2014-02-28 | Upgrade | Macquarie | Neutral to Outperform | |
| 2014-02-28 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | |
| 2014-01-28 | Downgrade | Morgan Stanley | Overweight to Equal Weight | |
| 2014-01-27 | Downgrade | CIMB | Outperform to Hold | |
| 2014-01-24 | Lower Price Target | Canaccord Genuity | Hold | $49.00 to $43.00 |
| 2014-01-24 | Downgrade | William Blair | Outperform to Market Perform | |
| 2014-01-24 | Lower Price Target | Jefferies Group | $46.00 to $40.00 | |
| 2014-01-24 | Lower Price Target | BMO Capital Markets | $47.00 to $43.00 | |
| 2014-01-17 | Downgrade | Macquarie | Outperform to Neutral | |
| 2013-10-25 | Boost Price Target | Jefferies Group | Hold | $40.00 to $46.00 |
| 2013-10-25 | Downgrade | Deutsche Bank | Buy to Hold | $58.00 to $54.00 |
| 2013-10-09 | Boost Price Target | Piper Jaffray | $54.00 to $59.00 | |
| 2013-10-08 | Initiated Coverage | Northland Securities | Market Perform | $44.00 |
| 2013-10-07 | Initiated Coverage | Northland Securities | Market Perform | |
| 2013-09-23 | Upgrade | Goldman Sachs | Buy | |
| 2013-01-25 | Reiterated | Mizuho | Neutral | $41 to $45 |
| 2012-10-22 | Reiterated | Mizuho | Neutral | $33 to $39 |
| 2012-07-19 | Downgrade | Feltl & Co. | Buy to Hold | $38 to $35.75 |
| 2012-04-27 | Upgrade | Feltl & Co. | Hold to Buy | $38 |
| 2012-04-27 | Reiterated | Mizuho | Neutral | $28 to $32 |
| 2012-03-28 | Downgrade | Feltl & Co. | Buy to Hold | |
| 2012-01-17 | Downgrade | Feltl & Co. | Strong Buy to Buy | $35 to $33.15 |
| 2011-12-20 | Upgrade | Feltl & Co. | Buy to Strong Buy | $39.10 to $35 |
| 2011-06-30 | Initiated | Feltl & Co. | Strong Buy | $40.40 |
| 2010-02-05 | Upgrade | Wells Fargo | Underperform to Market Perform |
| 2016-07-10 | Reiterated Rating | Bank of America Corp. | Hold | $65.00 |
| 2016-06-27 | Downgrade | Needham & Company LLC | Hold to Underperform | |
| 2016-04-27 | Reiterated Rating | BMO Capital Markets | Hold | |
| 2016-04-27 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-04-27 | Reiterated Rating | Needham & Company LLC | Hold |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In RMD 437 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 16.26M |
| BlackRock Inc. | 13.35M |
| FMR LLC | 7.29M |
| STATE STREET CORP | 6.46M |
| BlackRock Fund Advisors | 6.17M |
| WCM INVESTMENT MANAGEMENT/CA | 5.82M |
| Capital World Investors | 4.92M |
| BlackRock Institutional Trust Company, N.A. | 4.57M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.03M |
| NORTHERN TRUST CORP | 1.88M |
| Invesco Ltd. | 1.64M |
| CITADEL ADVISORS LLC | 1.49M |
| JPMORGAN CHASE & CO | 1.28M |
| LEGAL & GENERAL GROUP PLC | 1.11M |
| BlackRock Group LTD | 0.94M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| QUINN MICHAEL A | 0.20% (287000) | RMD / |
| FARRELL PETER C | 0.17% (240896) | NUVA / RMD / |
| Farrell Michael J. Chief Executive Officer | 0.16% (224395) | RMD / ZMH / |
| ROBERTS CHRISTOPHER G | 0.16% (224337) | RMD / |
| Douglas Robert Andrew President and COO ResMed Inc. | 0.08% (110063) | RMD / |
| PACE GARY W | 0.07% (100578) | PCRX / RMD / |
| PENDARVIS DAVID Chief Administrative Officer | 0.07% (99106) | RMD / SQNM / |
| Reiser Anne President - ResMed Europe | 0.06% (90711) | RMD / |
| Sandercock Brett Chief Financial Officer | 0.05% (71072) | RMD / |
| Hollingshead James President, Americas | 0.04% (61261) | RMD / |
| Sodhi Rajwant President, SaaS Business | 0.02% (25090) | RMD / |
| TAYLOR RONALD R | 0.02% (21751) | ACT / RLH / RMD / |
| Burt Carol | 0.02% (21640) | EVHC / RMD / WCG / |
| McHale Richard President, RC Business | 0.01% (14204) | RMD / |
| Darkin Donald Pres. SDB SBU | 0.01% (13684) | RMD / |
| WAREHAM JOHN P | 0.01% (13000) | RMD / STE / |
| SULPIZIO RICHARD | 0.01% (7420) | CA / RMD / |
UM